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Available online xxxxBackground: The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in al-
logeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking
centres.
Methods: This Retrospective, multicenter exploratory-validation analysis of 9103 patients, (55.5% male, median
age 50 years; 1–75 years range) with an allogeneic HSCT between 2010 and 2016 from a matched sibling (N=
8641; 95%) ormatched unrelated donor (N=462; 5%) for acutemyeloid (N=6432; 71%) or acute lymphoblastic
(N=2671; 29%) leukaemia inﬁrst complete remission, and reported by 240 centres in 30 countries to the bench-
mark database of the European Society for Blood and Marrow Transplantation (EBMT) searched for factors asso-
ciated with use of transplant techniques (standard N = 6375;70% or reduced intensity conditioning N =
2728;30%, respectively bone marrow N = 1945;21% or peripheral blood N = 7158;79% as stem cell source),
and their impact on outcome.
Findings: Treatment groups differed signiﬁcantly from baseline population (p b 0.001), and within groups regard-
ing patient-, disease-, donor-, and centre-related pre-transplantation risk factors (p b 0.001); choice of technique
did depend on pre-transplantation risk factors and centre (p b 0.001). Probability of overall survival at 5 years de-
creased systematically and signiﬁcantlywith increasing pre-transplantation risk score (score 2 vs 0/1HR: 1·2, 95%
c.i. [1·1–1·.3], p = 0.002; score 3 vs 0/1 HR: 1·5, 95% c.i. [1·3–1·7], p b 0.001; score 4/5/6 vs 0/1 HR: 1·9, 95% c.i.
[1·6–2·2], p b 0.001) with no signiﬁcant differences between treatment groups (likelihood ratio test on interac-
tion: p=0.40). Overall survival was signiﬁcantly associatedwith selection steps and completeness of information
(p b 0.001).
Interpretation: Patients' pre-transplantation risk factors determine survival, independent of transplant techniques.
Transplant techniques should be regarded as centre policy, not stratiﬁcation factor in benchmarking. Selection
criteria and completeness of data bias outcome. Outcomesmay be improvedmore effectively through better iden-
tifying pre-transplantation factors as opposed to reﬁnement of transplant techniques.
Funding: The study was funded by EBMT.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Research in context
Evidence before this study
To review previous evidence on the effect of conditioning and
stem cell source on outcome, we searched PubMed for articles
published in English using the MeSH terms “haematopoietic
stem cell transplantation/HSCT” or “HCT” or “BMT” and “condi-
tioning”, respectively “reduced intensity conditioning”, respec-
tively “standard conditioning”, respectively “stem cell source”,
respectively “peripheral blood”, respectively “bone marrow”. In
addition, we searched for “HSCT/HCT/BMT” and “benchmarking”.
Studies conﬁrmed that pre-transplantation risk factors, such as
patient age, donor type, disease and disease stage correlate with
overall survival but left open whether transplant techniques can
alter this pre-transplantation risk. Several reports claimed “re-
duced intensity conditioning” speciﬁcally for “elderly and frail pa-
tients”. Retro- and prospective studies, including two randomized
controlled trials provided conﬂicting results. Better information is
relevant for individual patients; it is relevantwhen benchmarking
is used to assess centre speciﬁc outcome. It is unknown whether
transplant techniques should be considered as centre policy or
as stratiﬁcation factor.
Added value of this study
This retrospective multicenter study in a homogeneous group
of patientswith awell-deﬁned diseaseﬁlls the gap in the evidence
base concerning the role of transplant techniques on pre-
transplantation risk. Type of technique is determined by patients'
criteria and centres' choice. Probability of overall survival at
5 years decreased systematically and signiﬁcantly with increasing
pre-transplantation risk, regardless of standard- or reduced inten-
sity conditioning, of bonemarrow or peripheral blood as stem cell
source. In addition, the study showed themajor impact of any se-
lection process and incomplete data on outcome.
Implications of all the available evidence
The results from this study indicate that transplant technique
should be considered as centre policy, rather than stratiﬁcation
factor in benchmarking. It indicates that focus should shift from
2 A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxx1ﬁne-tuning transplant techniques to better deﬁning and reporting
pre-transplantation risk factors. eloid or lymphoblastic leukaemia in 1st complete remission (1st CR). Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) pro-
vides a curative treatment for selected patients with severe congenital
or acquired disorders of the haematopoietic system, but remains associ-
ated with signiﬁcant morbidity and mortality, despite improvements
over the last decades [1–3]. Relapse of the primary disease or death
due to early or late treatment complications are themain determinants
of failure [4]. A wide range of patient-, donor-, disease-, and centre-
related pre-, peri-, and post-transplantation risk factors contributes to
ﬁnal outcome [1,3,5].
A simple score of ﬁve pre-transplantation factors was established
and validated 20 years ago to predict the risk for failure, and to permit
an integrated risk-adapted approach [6,7]. Patient selection, disease
classiﬁcation, disease treatment, donor choice and transplant tech-
niques have since changed [2–5,8,9]. New concepts including co-
morbidity index or disease risk score have beendeveloped to better pre-
dict outcome [10]. Pilot studies, based on carefully conducted animal
studies, have suggested that novel transplant technologies mightPlease cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.mitigate against the elevated mortality for high risk patients, and open
up transplantation for “elderly and frail patients” [11–13]. Pro- and ret-
rospective studies have yielded conﬂicting results [14–16].
The answer is relevant for individual patients but also when trans-
plant centres are compared for their performance. Benchmarking is
now advocated to improve patient outcome [17–20]. It is used in several
countries, and has been incorporated as an accreditation standard since
the 6th edition of the FACT-JACIE standards [21]. The bestmethod is not
deﬁned. The potential risk, to focus more on ranking than patient per-
spectives, has only recently been outlined [22].
Within the framework of an ongoing JACIE/EBMT project, we were
interested to learn more about the respective roles of transplant tech-
niques and pre-transplantation risks on ﬁnal outcome, and to ﬁnd out
about their respective place in benchmarking.We concentrated on con-
ditioning intensity and stem cell source. Conditioning is required to re-
duce rejection and disease burden; stem cells are needed to restore
hematopoiesis [1–3]. Both techniques present with a Janus-face [23].
Decreased conditioning intensity might reduce early mortality but in-
crease risk of relapse; peripheral blood as stem cell source can lead to
a more rapid engraftment, but to a higher rate of chronic graft-versus-
host disease (GvHD) [24].We focused on awell-deﬁned, homogeneous,
and recent patient cohort, with the most frequent indication for alloge-
neic HSCT, acute leukaemia [2,8,9]. We looked for factors associated
with the choice of transplant techniques and we asked whether the ef-
fect of well-known pre-transplantation risk factors would be modiﬁed
by the transplant techniques. We wanted to learn whether the latter
should be used as adjustment criteria for benchmarking, or regarded
as part of the centre's policy.
2. Methods
2.1. Study Design, Patient Selection and Final Patient Population
This retrospective observational analysis is an extract from the
EBMT megaﬁle (www.ebmt.org), locked at a speciﬁc time point, and
kept unmodiﬁed for benchmarking questions without re-contacting
centres. It holds information on 407,460 (196,175; 48% allogeneic) pa-
tients treated between 2010 and 2016 by an allogeneic HSCT for an ac-
quired haematological malignancy, and reported by 240 teams in 30
countries (Table 1). They correspond to approximately 80% of patients
with HSCT as listed in the EBMT activity survey within the same time
frame [8]. We concentrated on patients (adult and paediatric) with a
transplant from an HLA-identical sibling or HLA-matched unrelated
bonemarrow or peripheral blood stem cell donor for primary acutemy-
(see Supplementary Table 1), and information on the key risk factors
(see below) (Table 2) [11]. Patient survival data were updated as of Jan-
uary 1st, 2018. This ﬁnal cohort included 6375 patients (70%)with stan-
dard, 2728 patients (30%) with reduced intensity conditioning, 1945
patients (21%) with bone marrow, 7158 (79%) with peripheral blood
as stem cell source (Table 2). They represent about 10% of all allogeneic
HSCT in this benchmark cohort.
2.2. Deﬁnitions
We deﬁned acute leukaemia as primary, when “primary” was re-
ported to the database with the main diagnosis at time of diagnosis
and at time of transplant. The time intervals from diagnosis to 1stCR
and from 1stCR to transplant were categorized into two groups each:
≤3 months versus N3 months [5].
Donor type was restricted to four categories depending on donor-
recipientmatching (matched sibling donors ormatchedunrelated donors
only) and on donor and recipient sex: HLA-identical, HY− or HY+ sibling,
and HLA-matched, HY− or HY+ unrelated donors. HY+ refers to a female
donor for amale recipient, HY− to all other donor-recipient sex combina-
tions [23].-transplantation Risks and Transplant-Techniques in Haematopoietic
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Table 1
Steps of the selection process of the 9103 study patients out of 407,460 patientswith a haematopoietic stem cell transplant and reported to the EBMT benchmark ﬁle: selection criteria and
comparisons of overall survival between selected and excluded patients.a
Steps Exclusion criterion N initial N excl N end HR
(95% CI)b
Comment
Start Starting ﬁle 407,460 n.a.
Step 1 Year transplant b2010 407,460 211,285 196,175 ·94
(·93–·95)⁎⁎⁎
N2010 better
Step 2 Autologous HSCT 196,175 112,688 83,487 2·24
(2·20–2·28)⁎⁎⁎
Allogeneic HSCT worse
Step 3 Diagnosis not acute leukaemia 83,487 37,609 45,878 1·13
(1·.10–1·16)⁎⁎⁎
Acute leukaemia worse
Step 4 Cord blood as stem cell source 45,878 2042 43,836 ·84
(·78–·90)⁎⁎⁎
Non-cord blood donors better
Step 5 Missing informationc 43,836 4506 39,330 ·88
(·83–·94)⁎⁎⁎
Patients with full information better
Step 6 Non-primaryd acute leukaemia 39,330 3676 35,654 ·76
(·72–·80)⁎⁎⁎
Primary acute leukaemia better
Step 7 Non 1st CR 35,654 13,239 22,415 ·55
(·53–·56)⁎⁎⁎
1st CR better
Step 8 Donor not HLA-identical 22,415 13,233 9182 ·84
(·81–·88)⁎⁎⁎
HLA-identical donor better
Step 9 Time Dx-Tx N12 months 9182 79 9103 ·86
(·58–1·26)n.s.
No difference
Sub-group analysis No information time Dx-1st CR and 1st CR-Tx 9103 6517 2586 ·93
(·85–1·01)⁎
Patients with detailed information better
Dx-Tx: Time from diagnosis to transplant; Dx-1st CR: Time from diagnosis to 1st complete remission; 1st CR-Tx: Time from 1st complete remission to transplant.
a According to the STROBE checklist: (https://www.strobe-statement.org/index.php?id=available-checklists). For details of exclusions, and reasons to do so, see Methods section.
b Hazard ratios and 95% conﬁdence intervals in overall survival of remaining versus excluded patient population.
c Full information includes details in the report regarding age, sex of patient and donor, main disease and stage of the disease, donor type, stem cell source, and type conditioning.
d For deﬁnition, see Methods; in addition, time interval from diagnosis to 1st CR (if known) had to be b6 months.
n.s p ≥ 0.1.
⁎ p = 0.09.
⁎⁎⁎ p ≤ 0.0001.
Table 2
Characteristics of 9103 patients with a haematopoietic stem cell transplant for primary acute leukaemia (acutemyeloid leukaemia or acute lymphoblastic leukaemia) in 1st complete re-
mission between 2010 and 2016, depending on applied transplant technique.
Applied transplant techniques: conditioning and source of stem cells
0 MAB + BM 1 MAB + PB 10 RIC + BM 11 RIC + PB Total
Count Column valid N
%
Count Column valid N
%
Count Column valid N
%
Count Column valid N
%
Count Column valid N
%
Disease Prim.AML 980 56·9% 3193 68·6% 175 78·1% 2084 83·2% 6432 70·7%
Prim ALL 741 43·1% 1461 31·4% 49 21·9% 420 16·8% 2671 29·3%
Patient sex Male 961 55·8% 2597 55·8% 116 51·8% 1378 55·0% 5052 55·5%
Female 760 44·2% 2057 44·2% 108 48·2% 1126 45·0% 4051 44·5%
Patient age@trpl b20 years 719 41·8% 358 7·7% 28 12·5% 15 0·6% 1120 12·3%
20–40 years 496 28·8% 1822 39·1% 36 16·1% 170 6·8% 2524 27·7%
40–60 years 454 26·4% 2198 47·2% 100 44·6% 1292 51·6% 4044 44·4%
N60 years 52 3·0% 276 5·9% 60 26·8% 1027 41·0% 1415 15·5%
Karnofsky ≤80 284 16·5% 610 13·1% 40 17·9% 562 22·4% 1496 16·4%
90,100 1437 83·5% 4044 86·9% 184 82·1% 1942 77·6% 7607 83·6%
Donor Idsib, HY− 1249 72·6% 3330 71·6% 151 67·4% 1756 70·1% 6486 71·3%
Idsib, HY+ 400 23·2% 1110 23·9% 54 24·1% 591 23·6% 2155 23·7%
MatchUnrel, HY− 63 3·7% 190 4·1% 17 7·6% 138 5·5% 408 4·5%
MatchUnrel, HY+ 9 0·5% 24 0·5% 2 0·9% 19 0·8% 54 0·6%
Accredited by 2012 No 944 54·9% 2947 63·3% 127 56·7% 965 38·5% 4983 54·7%
Yes 777 45·1% 1707 36·7% 97 43·3% 1539 61·5% 4120 45·3%
Intvdiag-1stCR 0–3 months 623 91·9% 779 85·0% 54 83·1% 796 85·9% 2252 87·1%
3–6 months 55 8·1% 137 15·0% 11 16·9% 131 14·1% 334 12·9%
Intv1stCR-trpl 0–3 months 339 50·0% 475 51·9% 27 41·5% 467 50·4% 1308 50·6%
N3 months 339 50·0% 441 48·1% 38 58·5% 460 49·6% 1278 49·4%
Pre-score 0/1 999 58·0% 1511 32·5% 50 22·3% 131 5·2% 2691 29·6%
2 455 26·4% 1979 42·5% 67 29·9% 764 30·5% 3265 35·9%
3 222 12·9% 923 19·8% 65 29·0% 1010 40·3% 2220 24·4%
4/5/6 45 2·6% 241 5·2% 42 18·8% 599 23·9% 927 10·2%
Total 1721 100·0% 4654 100·0% 224 100·0% 2504 100·0% 9103 100·0%
• P-values for Chi-square tests: donor (p = 0·03); interval 1st CR-trpl (p = 0·42); patient gender (p = 0·63); all others (p b 0.001).
MAC: myeloablative conditioning; RIC: reduced-intensity conditioning. For deﬁnitions, see Methods.
BM: bone marrow; PB: peripheral blood.
Idsib: HLA-antigen matched sibling donor; MatchUnrel: HLA-antigen matched unrelated donor.
HY+: HY-antigen barrier positive; female donor for a male recipient; HY−: all other donor-recipient sex combinations.
Intv diag-1stCR: Time from diagnosis to achieving 1st complete remission.
Intv 1st CR-trpl: Time from 1st complete remission to transplant.
Prescore: see Methods section for explanation.
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4 A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxxConditioning intensity was used as previously deﬁned and classiﬁed
by the reporting team into standard or reduced intensity conditioning
[23]. Stem cell source was restricted to bone marrow or peripheral
blood; patients with cord blood or combined sources were excluded
(Table 1).
All types of graft-versus-host disease (GvHD) prophylaxis were in-
cluded, but ignored as factors in the analysis. Type of prophylaxis varied
from centre to centre, and there is no documented superior combina-
tion regarding overall survival than a calcineurin inhibitor with or with-
out methotrexate [9].2.3. Statistical Analysis
This complex analysis comprised a multi-step process. First, we
compared at each selection step overall survival of the included ver-
sus excluded patients (Table 1). For the ﬁnal group of 9103 patients,
a stratiﬁed Coxmodel (stratiﬁcation by conditioning) was used to in-
vestigate possible non-proportionality due to differently shaped
curves corresponding to conditioning intensity as reported in the lit-
erature [14–16]. The qualitative interaction (i.e. “crossing curves”)
could be resolved by incorporating the signiﬁcant and strong inter-
action between stem cell source (bone marrow versus peripheral
blood), and conditioning (standard versus reduced intensity condi-
tioning). The interaction term was then replaced by a 4-level factor
of the four combinations. Conditioning and stem cell source served
therefore as adjustment factors, without comparing directly the
types of transplant techniques with each other. All inference on the
other factors remained virtually the same and the replacement of
the interaction term by a 4-level covariate did facilitate the clinical
interpretation of the other hazard ratios.
We then searched for factors associated with use of transplant
technique. The likelihood of patients to receive reduced intensity
conditioning was estimated by a logistic regression model using cal-
endar year, patient age, Karnofsky (adult)/Lansky (paediatric) per-
formance score, disease and donor type. A second estimate was
obtained by adding the centre identiﬁcation itself and whether the
time between diagnosis and 1st CR was indeed reported by the re-
spective centre. The former was used to estimate the average likeli-
hood for the study population of receiving a reduced intensity
conditioning based on patient pre-transplantation characteristics.
The latter incorporated centre characteristics, i.e. the willingness to
perform a reduced intensity conditioning procedure, and the centres'
quality of reporting. In a similar approach, we estimated the likeli-
hood of receiving peripheral blood compared to bone marrow as
stem cell source.
For factors associated with outcome, the main endpoint was the
probability of overall survival up to 5 years in a Cox model [10]. We
used a modiﬁed EBMT pre-transplantation risk score [5]. Patient age
(b20 years, 20–40 years, 40–60 years, N60 years; 0–3 score points),
donor type (matched sibling or matched unrelated; 0–1 score points),
HY status (HY− vs HY+; 0–1 score points), and Karnofsky/Lansky
score (N80 versus ≤80; 0–1 score points) contributed to the ﬁnal score
(score 0 to maximum 6) (Table 2). As macro- and micro-economic co-
variates at the centre level, we used the country speciﬁc Human Devel-
opment Index (www.hdi.org) and accreditation status [25]. Calendar
year was included as a continuous covariate.
The analyses were ﬁrst performed for the 6432 patients with acute
myeloid leukaemia. Having developed the survival model, we checked
that the resultswere valid also for the 2671 patientswith acute lympho-
blastic leukaemia in 1st CR separately (data not shown). After checking
that no signiﬁcant interaction took place between the diseases and the
other covariates (Supplementary Table 1), we ﬁnally analyzed the com-
bined data set of 9103 patients, but adjusting for disease to increase the
power of the estimates.
The analyses were performed in SPSS version 25.Please cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.2.4. Organizational and Ethical Aspects
EBMT teams are required to obtain patients' consent for data transfer
to EBMT in accordance with appropriate internal approval for their
transplant programs and European Data Protection Regulations
(GDPR) if applicable (https://eugdpr.org/). Adherence to these require-
ments and accuracy of data reporting is regularly audited within the
JACIE accreditation process. The data set was locked at time of transfer
to the statistical ofﬁce. On purpose, to reﬂect a benchmarking process
at time x, no attempt was made nor could be made to retrieve missing
data. According to the laws in the Netherlands and Switzerland, no
ethics approval was mandated for this analysis with anonymized data.
3. Results
3.1. Selection Process
The benchmark ﬁle population was reduced in 9 steps from the ini-
tial 407,460 patients to the ﬁnal 9103. This process showed a systematic
and signiﬁcant change in overall survival at 5 years at each step of the
selection process, with one exception. Results conﬁrmed the well-
known roles of year of transplant, main donor type, main disease cate-
gory, cord blood as stem cell source, primary versus secondary leukae-
mia, and remission status (all p b 0.001) (Table 1). As a novel ﬁnding,
we identiﬁed a signiﬁcantly worse overall survival for patients with
missing information (HR: 0·88; 0·83–·94) (p b 0.001), and a signiﬁcant
correlation between missing information, accreditation status and the
age of the patients. Patients with incomplete information were more
likely to be reported from non-accredited centres (p b 0.001) and
were younger (p b 0.001), with a higher proportion of paediatric pa-
tients in non-accredited (18·4%) than accredited centres (10·2%). How-
ever, the proportion of patients with incomplete information was 20%
for paediatric patients in both, accredited and non-accredited centres;
it was 11·2% for adult patients in non-accredited, 5·5% in accredited
centres (Supplementary Table 2a).
Information on the degree of matching (matched or mismatched)
was missing in a much higher proportion of unrelated donor than sib-
ling donor transplants (Table 1; step 8), leading to an under representa-
tive proportion of unrelated HSCT of only 5%.
3.2. Patient Population
There were signiﬁcant differences between patients with acute my-
eloid and acute lymphoblastic leukaemia, between patients with stan-
dard or reduced intensity conditioning, and between patients with or
without a known time interval from diagnosis to 1st CR (Table 2). Pa-
tients with primary acute lymphoblastic leukaemia were more likely
to be males (60·2% vs 53·5%; p b 0.001), were younger (59·6%
b40 years old vs 31·9%; p b 0.001), had lower Karnofsky/Lansky scores
(18·1% ≤80 vs 15·7%; p= 0.005), but lower pre-transplantation scores
(76·4% score 0–2 vs 60·8%; test for trend 0+1 vs 2 vs 3 vs 4+5+6=
p b 0.001).
Patients with reduced intensity conditioning were more likely to
have acute myeloid leukaemia, (83% vs 66%; p b 0.001), were older
(39·8% N60 years old vs 5·1%; p b 0.001), showed a higher proportion
with low performance score (22% ≤80 vs 14%; p b 0.001), were prefer-
entially given peripheral blood as stem cell source (92% vs 73%; p b
0.001) and had a higher proportion of unrelated donor transplants
(6·5% vs 4·5%; p = 0.001) (Table 2).
Patients with information on time sub-intervals (time from diagno-
sis to 1st CR and time from 1st CR to transplant; N = 2586) were more
likely to be reported from accredited than non-accredited centres
(42·0% vs 17·2%; p b 0.001), and to have a lower proportion of patients
with a low pre-score of 0–2 (56·9% vs 68·8%; p b 0.001) (Supplemen-
tary Table 2b). Overall survival of patients with full information, in-transplantation Risks and Transplant-Techniques in Haematopoietic
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5A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxxcontrast, was not different. Hence, centreswithmissing information had
a higher proportion of lower risk patients.
3.3. Factors Associated With Transplant Practice
The analysis showed no apparent consistency in the choice of condi-
tioning regimen across transplant centres, even when patients showed
the same pre-transplantation characteristics (Supplementary Fig. 1a).Fig. 1. Factors associatedwith choice of transplant technique for 9103 patients with a haematop
1st complete remission. The graphs illustrate the probability of choice without (x-axis) and wit
team) as factor. Each dot represents one patient. For details, see Methods section. a: Choice of r
(=acute lymphoblastic leukaemia). R-square: 0.51 (top) and 0.46 (bottom). b: Choice of peri
Bottom: ALL; Left: standard conditioning; Right: reduced intensity conditioning. R-square: 0.22
Please cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.The same applied to the likelihood of receiving peripheral blood com-
pared to bone marrow as stem cell source (Supplementary Fig. 1b).
Age (p b 0.001), Karnofsky's score (p = 0.001), disease (p b 0.001)
and centre (ﬁxed factor, p b 0.001) were highly signiﬁcant in a logistic
regression model for choice of conditioning, while donor type (p =
0.80) and calendar year (p = 0.12) were not. For the choice of type of
stem cells, calendar time (p = 0.001), age (p b 0.001), Karnofsky's
score (p = 0.01), donor type (p = 0.017), conditioning (p b 0.001)oietic stem cell transplant for primary acutemyeloid or acute lymphoblastic leukaemia in
h (y-axis) considering transplant centre (CIC= Centre identiﬁcation code of transplanting
educed intensity conditioning (RIC). Top: AML (=acute myeloid leukaemia); Bottom: ALL
pheral blood as stem cell source, by patients' characteristics and conditioning. Top: AML;
(top left), 0.13 (top right), 0.27 (bottom left), 0.24 (bottom right).
-transplantation Risks and Transplant-Techniques in Haematopoietic
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Fig. 1 (continued).
6 A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxxand centre (ﬁxed factor, p b 0.001) were highly signiﬁcant, while dis-
ease was not. The apparent arbitrariness, in terms of patient character-
istics, to decide for or against a given transplant technology is reﬂected
by the scattergram when the likelihood was calculated with or without
centre identiﬁcation code as a ﬁxed factor in the model (Fig. 1a and b).3.4. “Standard” Risk Factors and Univariate Outcome
Probability of overall survival at 5 years was 59% for patients with
primary acute lymphoblastic leukaemia, 55% for patients with primary
acutemyeloid leukaemia (Fig. 2a). The survival pattern showed no indi-
cation for a ‘Janus face’ of conditioning intensity and stem cell source.
Early overall survival at day 30 was 99% for the whole group. The anal-
ysis conﬁrmed previously deﬁned risk factors with a similar pattern for
the four subgroups. Overall survival decreased systematically with in-
creasing recipient age from 64% at 5 years for the b20 years old to 48%
for the N60 years old patients (p b 0.001) (Supplementary Fig. 2a),
and with increasing histoincompatibility (p b 0.001) (Supplementary
Fig. 2b). Patients with a Karnofsky/Lansky score N 80 showed an overall
survival of 58% at 5 years compared to 49% for thosewith a score of 80 or
lower (p b 0.001) (Supplementary Fig. 2c). Combined in a score as sum-
marized above, overall survival decreased stepwise from close to 80% at
5 years with score 0; 58% with score 2; 50% with score 3, to 45% with
score 4 to less than 40% with scores 5and6 (p b 0.001) (Supplementary
Fig. 2d).Please cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.3.5. Multivariate Effects of Pre-existing and Treatment-related Risk Factors
on Outcome
Overall survival decreased in a risk adjusted Cox model systemati-
cally, signiﬁcantly and stepwise with increasing pre-transplant risk
score in a four group analysis: (score 2 vs 0/1 HR: 1·2, 95% c.i.
[1·1–1·3], p = 0.002; score 3 vs 0/1 HR: 1·5, 95% c.i. [1·3–1·7], p b
0.001; score 4/5/6 vs 0/1HR: 1·9, 95% c.i. [1·6–2·2], p b 0.001), whether
source of stem cells and conditioning were included in the model to-
gether with their interaction or as stratiﬁcation factors to allow for
non-proportionality. There was no indication at all that conditioning
or source would alter the inherent pre-transplantation risk (likelihood
ratio test on interaction: p = 0·40) (Fig. 2b; Table 3).
The same effect was observed, with obvious loss of power, when the
four groups of conditioning and stem cell sourcewere analyzed indepen-
dently. Therewas one exception in the small group of patients (N=224)
with reduced intensity conditioning and bone marrow as source (Sup-
plementary Table 3).
The analysis was not designed to compare the four groups of condi-
tioning and stem cell source. With all limitations, when acute myeloid
leukaemia and acute lymphoblastic leukaemia patients were analyzed
separately, the analysis showed no signiﬁcant differences between the
four groups for patients with acute myeloid leukaemia. It indicated sig-
niﬁcant differences for patients with acute lymphoblastic leukaemia,
and best survival for patientswith standard conditioning and bonemar-
row as source (Table 3).-transplantation Risks and Transplant-Techniques in Haematopoietic
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Fig. 2. Probability of overall survival of 9103 patients with a haematopoietic stem cell transplant for primary acute myeloid or acute lymphoblastic leukaemia in 1st complete remission
during the years 2010 to 2016. a: Overall survival for thewhole group, bymain disease. AML=acutemyeloid leukaemia; ALL= acute lymphoblastic leukaemia. b: Overall survival by pre-
transplant-risk score. The curves represent probability of overall survival, as evaluated for a patientwith a haematopoietic stem cell transplant for acutemyeloid leukaemia in 1st complete
remission in 2010, in an accredited centre in a country with the highest tertile for Human Development Index, using standard conditioning and peripheral blood as stem cell source. The
survival curves aremultivariately adjusted for accreditation, calendar year, HumanDevelopment Index, conditioning and source of stemcells. Pre-transplant scores are divided by scores 0/
1, 2, 3, 4/5/6 (for details, see Methods section).
7A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxx3.6. Additional Factors
The multivariate analysis conﬁrmed a better overall survival in
accredited centres (HR: ·886, 95% c.i. [·814–·965], p = 005), and a de-
crease of overall survival over calendar years time (HR: 1·031, 95% c.i.
[1·007–1·055], p = 010, per year). It conﬁrmed the lower probability
of overall survival for patientswith a longer time interval fromdiagnosis
to 1st CR (p b 0.001), possibly reﬂecting the need for additional chemo-
therapy to achieve remission [5]. The effectwasmore pronounced in pa-
tients with acute lymphoblastic leukaemia (Supplementary Fig. 3). As
previously described, the total time from diagnosis to transplant, not
considering the subintervals, had no effect on outcome [5].Please cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.4. Discussion
This retrospective cohort analysis provided clear answers regarding
both, factors associated with choice of transplant technique, and factors
associated with outcome. As shown in this large homogeneous patient
population, centre preference and pre-transplantation patients' charac-
teristics determined the choice of transplant techniques, e.g. condition-
ing intensity and stem cell source. Pre-transplantation properties were
predictive for overall survival. Overall survival at 5 years decreased
systematically and stepwise from close to 80% to less than 40%, all in pa-
tients with acute leukaemia in 1st CR. No preferential type of condition-
ing changed this pattern or reduced mortality for patients with high-transplantation Risks and Transplant-Techniques in Haematopoietic
019
Table 3
Factors associated with probability of overall survival. Data present the risk of mortality
(Hazard ratios; HR, with 95% conﬁdence intervals) for 9103 patients with a
haematopoietic stem cell transplant for acute leukaemia (acute myeloid leukaemia:6432;
acute lymphoblastic leukaemia:2671) in 1st complete remission, depending on pre-trans-
plant risk factors (pre-score), centre's macro- and micro-economic factors, and choice of
transplant technique. The model allowed for any interaction of the disease with the other
risk factors.
Sig. HR 95.0% CI for Exp(B)
Lower Upper
Pre-score (0/1) 1·0
2 ·002 1·187 1·063 1·326
3 ·000 1·490 1·318 1·684
4/5/6 ·000 1·902 1·634 2·215
Accredited by 2012 ·005 ·886 ·814 ·965
Percentile group of HDI (high vs other) ·380 1·041 ·952 1·139
Year of treatment (per year) ·010 1·031 1·007 1·055
Evaluation for AML
MAC + BM (ref cat) 1·0
MAC + PB ·436 1·059 ·917 1·221
RIC + BM ·978 1·004 ·743 1·358
RIC + PB ·966 ·997 ·850 1·168
Evaluation for ALL:
MAC + BM (ref cat) 1·0
MAC + PB ·001 1·410 1·156 1·720
RIC + BM ·207 1·486 ·803 2·748
RIC + PB ·000 1·775 1·389 2·270
• Adding interactions with disease was necessary to obtain a good proportional hazards
model ﬁt analyzing both diseases together (to increase the power for the estimates of
the patient-related effects).
• All interactions between disease and the risk factors were non-signiﬁcant except for the
effect of conditioning and source of stem cells being modiﬁed by the disease (p= 0.001).
The dose-response effect of the Pre-scoremay be assumed to be the same in AML and ALL.
•When estimating the samemodel separately among AML resp. ALL, theHR'swere almost
identical to the averaged effects in this table.
•No interpretation of the differing HR's for conditioning and source of stem cells between
AML and ALL are attempted since the very deﬁnition of RIC could be different among AML
and ALL and varying over calendar time and centres. Conditioning is merely used as a co-
variate to remove bias in the estimates of the pre-score and other patient related factors
due to a possible correlation with conditioning and/or source of stem cells.
•MAC:myeloablative conditioning= reduced intensity conditioning; RIC: reduced-inten-
sity conditioning. For deﬁnitions, see Methods.
Sig: p value; BM: bone marrow; PB: peripheral blood. HDI: Human Development Index.
8 A. Gratwohl et al. / EClinicalMedicine xxx (xxxx) xxxpre-transplantation risk scores [13–16]. In addition, the study revealed a
signiﬁcant impact of the selection process, and a signiﬁcantly worse
overall survival for patients with incomplete information. These are
novel ﬁndings, with direct consequences regarding benchmarking.
Benchmarking aims to improve the quality of patient care and out-
comes [17–20]. Its success depends on widespread perception of ‘fair-
ness’ through risk-adjustment for differences in patient population
characteristics. Withholding known information, intentionally or not,
can introduce bias. As shown in this study, completeness of information
on known pre-transplantation risk factors appears to be essential for
proper risk-adaptation. There is a scarcity of published information
about variations between centres in quantity and quality of patient
data reporting. The standards of the JACIE accreditation process aim to
assure quality in this respect. Thus, the concept of ‘fairness’ becomes a
mutual responsibility between a centre and the benchmarking system.
The analysis revealed additional novel elements. We found no signs
of a ‘Janus-face’ effect of the transplant techniques [23]. The excellent
day 100 survival precludes any early comparison. Regarding late sur-
vival, some patients with acute leukaemia in 1st complete remission
are cured before the transplant, independent of conditioning [7]. Sec-
ond, about one third of patients with matched donors never ever de-
velop any graft-versus-host disease [26]. There is no tool yet available
to identify such patients before the transplant.
Major caveats remain. There were signiﬁcant differences between
the groupswhich could not be adjusted for.We did not includemethods
of graft-versus-host disease prevention, or the “post-transplant cyclo-
phosphamide” concept [8,9].Please cite this article as: A. Gratwohl, R. Duarte, J.A. Snowden, et al., Pre
Stem Cell Transplantation for ..., https://doi.org/10.1016/j.eclinm.2019.07.Information on “matching” of donor and recipient was too fre-
quently missing, especially in unrelated donor transplants, leading to a
too low number of unrelated HSCT compared to current practice [8,9].
This practicemight reﬂect a general problemof the database. “Matched”
as indicated by the reporting team, and used in the analysis, is still ill de-
ﬁned and might range from an 8/8 HLA-antigen to a 12/12 HLA-allelic
match or beyond [9]. Transplant organizations are challenged to better
deﬁne categories and to improve reporting.
Performance scores may fail to accommodate co-morbidities or the
complex frailty of older patients [27]. Molecular, cytogenetic, and mini-
mal residual disease statuswas not available, informationwhich is espe-
cially relevant for individual decision-making [7]. Still, no attempt was
made to retrieve additional data in order to reﬂect a status quo at any
time of a benchmarking process. The large numbers and the consistency
of the ﬁndings provide sufﬁcient validity to the report.
The results provide guidance for future benchmarking strategies.Wide
variations in infrastructure and use of transplant techniques are well de-
scribed [4,8,9]; it may be challenging to incorporate the impact of these
variations. Reassuringly and based on our results, transplant techniques
should be considered a centre-speciﬁc (“policy”) property rather than to
beused as adjustment factor. In addition, “completeness of data reporting”
almost becomes a surrogate marker for quality of transplant outcome.
In the current era of personalized medicine, HSCT has to provide a
better outcome regarding overall survival, quality of life and costs. To
achieve this goal, risks and beneﬁts of HSCT have to be balanced contin-
uously from diagnosis on with those of a non-transplant strategy [28].
Decisions should then be based on deﬁned data, collected and analyzed
according to the WHO principles [5,7,8,29].
Hence, assessing transplant centre quality through any accreditation
or ‘benchmarking’ system should concentrate on completeness of data
reporting, must deﬁne any selection beforehand, and must strive to in-
clude non-transplanted patients as well. The analysis also supports the
hypothesis that transplant outcomes may be improvedmore effectively
through identifying hitherto ‘hidden’ pre-transplantation factors as op-
posed to reﬁnement of transplant techniques.
The implications of this report may apply to other disease categories
as well, to other cellular treatment approaches, or when developing
novel machine learning tools [30].
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